(Adds details)
GENEVA, April 12 (Reuters) - Some 14.1 million doses of the
Pfizer PFE.N BioNTech 22UAy.DE COVID-19 vaccine have been
allocated to 47 countries and economies for delivery in the
second quarter of this year, the Gavi Vaccine Alliance said on
Monday.
Brazil, Colombia, Mexico, the Philippines, South Africa, and
Ukraine are set to be among the main recipients of the Pfizer
vaccine between April and June, according to Gavi, which
co-leads the COVAX facility with the World Health Organization
(WHO) and other partners.
The COVAX programme offers a lifeline to low-income
countries in particular, allowing them to inoculate health
workers and others at high risk, even if their governments have
not managed to secure vaccines from the manufacturers.
Australia, Britain, Kuwait, and the United Arab Emirates are
due to receive their first shots via COVAX with the Pfizer
doses, which is "based on current knowledge of COVID-19 vaccine
supply availability", Gavi said in a statement.
The programme delivered nearly 38.4 million doses of
COVID-19 vaccines to 102 countries across six continents, six
weeks after it began to roll out supplies, Gavi said last
Thursday. Deliveries of the AstraZeneca (NASDAQ:AZN) AZN.L vaccine to 142
participants under a previously announced round were underway,
"with some delays" that may extend deliveries past May, Gavi
said on Monday.
Reduced availability delayed some deliveries in March and
April, and much of the output of the Serum Institute of India,
which makes the AstraZeneca vaccine, is being kept in India,
where the number of daily infections is spiralling.
The chief executive of Gavi, Seth Berkley, said last Friday
that COVAX aimed to deliver one third of a billion COVID-19
doses by mid-year, on the way to more than 2 billion in 2021.
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
UPDATE 1-Brazil, Mexico, Philippines among those due to get Pfizer shots from COVAX in Q2 - statement
Published 04/12/2021, 08:35 PM
Updated 04/12/2021, 08:40 PM
UPDATE 1-Brazil, Mexico, Philippines among those due to get Pfizer shots from COVAX in Q2 - statement
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
UPDATE 1-Brazil, Mexico, Philippines among those due to get Pfizer shots from COVAX in Q2 - statement
Latest comments
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.